Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Development of New NRTI Festinavir Continues

February 2011

Promising news about a new NRTI called festinavir (OBP-601) continued through its Phase 1 and 2 studies. The HIV drug is chemically similar to an earlier NRTI called d4T (stavudine), although it doesn't appear to cause the same disruption of mitochondria, or the "power centers" inside cells. This disruption led to a serious condition called mitochondrial toxicity and contributed to significant body shape changes that many experienced earlier in the epidemic.

Early results so far suggest the drug is well tolerated and is effective against strains of HIV resistant to current NRTIs on the market. It may work better in those with resistance to lamivudine (Epivir), emtricitabine (Emtriva) and efavirenz (Sustiva). The drug is dosed once a day. More study is obviously needed in larger numbers of individuals, but hopefully within a couple of years festinavir can be shown to add some unique benefit to current treatments.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More on NRTIs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement